ClinicalTrials.gg
Active, not recruitingNCT04738942Updated Jun 15, 2026Results posted

A Study of Intravenous Vedolizumab Administered Every 4 Weeks in Japanese Participants With Moderate to Severe Ulcerative Colitis or Crohn's Disease

A Phase 3 interventional study of Vedolizumab in Ulcerative Colitis and Crohn's Disease, sponsored by Takeda. Active, not recruiting at 20 sites in Japan. Open to participants aged 18 Years to 80 Years. Per ClinicalTrials.gov, last updated 2026-06-15.

Sponsored by Takeda · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
56
Allocation
Non-randomized
Ages
18 Years to 80 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 38 studies testing vedolizumab in Colitis, Ulcerative — 5 open to participants now, 9 under way, 6 of them phase 3. vedolizumab · Colitis, Ulcerative.

Enrollment
28th of 38
56 · median 110
Started
2021
with 4 others
Phase 3
14 of 38
3 open now
Registered
26th of 38
by date
Lead sponsor
22 of 38
Takeda

Among the 38 studies testing vedolizumab in Colitis, Ulcerative, this one is the 28th largest by enrollment, is one of 5 that started in 2021, is one of 14 in phase 3, and was the 26th registered.

Colitis, Ulcerative

1,854 studies on the registry are indexed under Colitis, Ulcerative; 473 are open to participants now.

Browse Colitis, Ulcerative studies →

Open to participants now

5 of the 38 studies testing vedolizumab in Colitis, Ulcerative are open now, in 12 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 5 open studies →

About vedolizumab

vedolizumab: first FDA approval 2014 (ENTYVIO), first EMA approval 2014. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 307 Colitis, Ulcerative studies recruiting now, 134 (44%) set no upper age limit and 136 (44%) stop at 75 or younger; 71 take children under 18; 41 take healthy volunteers.

This study: 18 Years to 80 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 38 studies testing vedolizumab in Colitis, Ulcerative, or all of them as a file.
02

Study summary

The main aim of the study is to learn if 4-weekly vedolizumab improves symptoms of Japanese participants with moderate to severe ulcerative colitis (UC) or Crohn's disease (CD). Vedolizumab is commercially available in Japan for 8-weekly treatment but not for 4-weekly treatment.

The study doctors will also monitor side effects from the study treatment.

This study will take place in Japan.

At the first visit, the study doctor will check if each person can take part. For those who can take part, participants will receive vedolizumab intravenously once every 4 weeks. After 3 infusions of vedolizumab (which will be 12 weeks of treatment), the study doctor will assess if symptoms of the participants have improved.

Participants who do not have improved symptoms after 12 weeks of treatment with vedolizumab will stop this treatment. Then, they will visit the study clinic 16 weeks after their last infusion of vedolizumab for a final check-up.

Participants who have improved symptoms after 12 weeks of treatment with vedolizumab will continue to receive vedolizumab every 4 weeks. Then, after their last infusion of vedolizumab, the participants will visit the study clinic 16 weeks later for a final check-up. Finally, the study clinic will make a phone call to each participant 6 months after their last infusion to check if they have any health problems.

03

Conditions studied

  • Ulcerative Colitis
  • Crohn's Disease
04

Who can participate

Ages eligible
18 Years to 80 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

UC cohort

  1. The participant has moderate to severe UC, who had previously shown clinical response in initial treatment with commercially available vedolizumab IV, then experienced secondary loss of response during maintenance therapy with commercially available vedolizumab IV Q8W.

    Previous "clinical response" is to be judged by the investigators referring to one of the following criteria.

    • Reduction of >=2 points and >=25% in modified Mayo score, and a decrease of >=1 point in rectal bleeding subscore or rectal bleeding subscore of =\<1, from the start of initial treatment with commercially available vedolizumab IV.
    • Reduction of >=2 points and >=25% in partial Mayo score, and a decrease of >=1 point in rectal bleeding subscore or rectal bleeding subscore of =\<1, from the start of initial treatment with commercially available vedolizumab IV.
    • Significant improvement on endoscopy (i.e., a decrease of >=2 points in Mayo endoscopic subscore).

    "Secondary loss of response" is to be judged by the investigators referring to one of the following criteria.

    • Increase of >=2 points in modified Mayo score, and an increase of >=1 point in rectal bleeding subscore or rectal bleeding subscore >=2, from the start of maintenance therapy with commercially available vedolizumab IV.
    • Increase of >=2 points in partial Mayo score, and an increase of >=1 point in rectal bleeding subscore or rectal bleeding subscore >=2, from the start of maintenance therapy with commercially available vedolizumab IV.
    • Significant deterioration on endoscopy (i.e., an increase of >=2 points in Mayo endoscopic subscore).
  2. The participant has active UC as determined by a modified Mayo score of >=5 at baseline (within 10 days prior to the start of treatment phase), with a Mayo rectal bleeding subscore of >=1 at baseline (within 10 days prior to the start of treatment phase) and a Mayo endoscopic subscore of >=1 as assessed by the central reader.

CD cohort

  1. The participant has moderate to severe CD, who had previously shown clinical response in initial treatment with commercially available vedolizumab IV, then experienced secondary loss of response during maintenance therapy with commercially available vedolizumab IV Q8W.

    Previous "clinical response" is to be judged by the investigators referring to one of the following criteria.

    • Reduction of >=70 points in CDAI score from the start of initial treatment with commercially available vedolizumab IV.
    • Reduction of >=3 points in HBI score from the start of initial treatment with commercially available vedolizumab IV.

    "Secondary loss of response" is to be judged by the investigators referring to one of the following criteria.

    • Increase of >=70 points in CDAI score from the start of maintenance therapy with commercially available vedolizumab IV.
    • Increase of >=3 points in HBI score from the start of maintenance therapy with commercially available vedolizumab IV.
  2. The participant has active CD as determined by a CDAI score of >=220 at baseline (within 10 days prior to the start of treatment phase).
  3. The participant has a C-reactive protein (CRP) level >3.0 mg/L during the screening phase.

Exclusion criteria

Exclusion Criteria:

  1. The participant has had extensive colonic resection, subtotal or total colectomy.
  2. The participant has received any of the or approved non-biologic therapies (e.g., cyclosporine, tacrolimus or tofacitinib, except for those specifically listed as permitted medications) for the treatment of underlying disease within 30 days or 5 half-lives of screening (whichever is longer).
  3. The participant has received any investigational or approved biologic or biosimilar agent other than vedolizumab within 60 days or 5 half-lives of screening (whichever is longer).
  4. The participant has a active infection (e.g., pneumonia, pyelonephritis or coronavirus disease 2019 [COVID-19]) within 30 days prior to screening or during screening, or has an ongoing chronic infection.
  5. The participant has known or suspected intolerance or to vedolizumab or closely related compounds, or any of the vedolizumab IV .
  6. The participant has active cerebral/meningeal disease, or signs/symptoms of progressive multifocal leukoencephalopathy (PML) or any history of PML at screening.
Terms in these criteria, in plain language(4)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Excipients

The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
56 participants (actual)

Study arms

  • Experimental
    Vedolizumab 300 mg in UC cohort

    Vedolizumab 300 mg, IV infusion, for up to 12 weeks Q4W for Treatment phase, and until the date of marketing approval of vedolizumab IV Q4W or study termination for Extension phase.

    Drug: Vedolizumab

  • Experimental
    Vedolizumab 300 mg in CD cohort

    Vedolizumab 300 mg, IV infusion, for up to 12 weeks Q4W for Treatment phase, and until the date of marketing approval of vedolizumab IV Q4W or study termination for Extension phase.

    Drug: Vedolizumab

Interventions

06

What researchers measure

Primary outcomes

  1. UC Cohort: Percentage of Participants With Clinical Response at Week 12 Based on Modified Mayo Score

    Clinical response was defined as a reduction of greater than or equal to (\>=) 2 points and \>=25 percent (%) in modified mayo score, and a decrease of \>=1 point in rectal bleeding sub-score or rectal bleeding sub-score of less than or equal to (\<=) 1 from baseline (Week 0). Mayo score was an instrument designed to measure disease activity of UC. Modified mayo score consisted of 3 sub-scores: stool frequency, rectal bleeding, and mayo endoscopic sub-score (findings on endoscopy), each graded from 0 to 3 with higher scores indicating more severe disease. These scores were summed to give a total score range of 0 to 9. Here, a higher score indicated more severe disease.

    Time frame: At Week 12

  2. CD Cohort: Percentage of Participants With Clinical Response at Week 12

    Clinical response was defined as a reduction of \>=70 points in Crohn's Disease Activity Index (CDAI) score from baseline (Week 0). A CDAI was a multi-item instrument that measured severity of active Crohn's Disease monitored over 7 days included participant reported symptoms, physician-assessed signs, and laboratory markers. CDAI total score was equal to sum of weighted scores for subjective items (number of liquid/soft stools, degree of abdominal pain, general well-being); and objective items (use of anti-diarrhoeal medication, abdominal mass, haematocrit, presence of extraintestinal manifestation, body weight). CDAI scores ranged approximately from 0 to 600, higher scores indicated greater disease activity.

    Time frame: At Week 12

Secondary outcomes

  1. UC Cohort: Percentage of Participants With Clinical Remission at Week 12 Based on Modified Mayo Score

    Clinical remission was defined as a modified Mayo score of less than or equal to (\<=) 2, and no individual sub-score greater than (\>) 1. Mayo score was an instrument designed to measure disease activity of UC. Modified Mayo score consisted of 3 sub-scores: stool frequency, rectal bleeding, and Mayo endoscopic sub-score (findings on endoscopy), each graded from 0 to 3 with higher scores indicating more severe disease. These scores were summed to give a total score ranged of 0 to 9. Here, a higher score indicated a more severe disease.

    Time frame: At Week 12

  2. UC Cohort: Percentage of Participants With Mucosal Healing at Week 12

    Mucosal healing was defined as a Mayo endoscopic sub-score of \<=1, in participants with baseline Mayo endoscopic sub-score of \>=2. Mayo score consisted of 4 sub-scores: stool frequency, rectal bleeding, mayo endoscopic sub-score (findings on endoscopy) and physician's global assessment, each graded from 0 to 3 with higher scores indicating more severe disease. These scores were summed to give a total score ranged of 0 to 12. Here, a higher score indicated a more severe disease.

    Time frame: At Week 12

  3. UC Cohort: Percentage of Participants With Corticosteroid-Free Remission Based on Partial Mayo Score

    Corticosteroid-free remission was defined as participants using oral corticosteroids at baseline (Week 0) who have discontinued oral corticosteroids and were in clinical remission based on partial Mayo score at Week 52. Clinical remission based on partial Mayo score was defined as a partial Mayo score of =\<2, and no individual sub-score \>1. Mayo score was an instrument designed to measure disease activity of UC. Partial Mayo score consists of 3 sub-scores: stool frequency, rectal bleeding, and physician's global assessment, each graded from 0 to 3 with higher scores indicated more severe disease. These scores are summed to give a total score range of 0 to 9. Here, higher scores indicated more severe disease.

    Time frame: At Week 52

  4. CD Cohort: Percentage of Participants With Clinical Remission at Week 12

    Clinical remission was defined as a CDAI score of \<=150. A CDAI was a multi-item instrument that measured severity of active Crohn's Disease monitored over 7 days included participant reported symptoms, physician-assessed signs, and laboratory markers. CDAI total score was equal to sum of weighted scores for subjective items (number of liquid/soft stools, degree of abdominal pain, general well-being); and objective items (use of anti-diarrhoeal medication, abdominal mass, haematocrit, presence of extraintestinal manifestation, body weight). CDAI scores ranged approximately from 0 to 600, higher scores indicating greater disease activity.

    Time frame: At Week 12

  5. CD Cohort: Percentage of Participants With Enhanced Clinical Response at Week 12

    Enhanced clinical response was defined as a reduction of \>=100 points in CDAI score from baseline (Week 0). A CDAI was a multi-item instrument that measured severity of active Crohn's Disease monitored over 7 days included participant reported symptoms, physician-assessed signs, and laboratory markers. CDAI total score was equal to sum of weighted scores for subjective items (number of liquid/soft stools, degree of abdominal pain, general well-being); and objective items (use of anti-diarrhoeal medication, abdominal mass, haematocrit, presence of extraintestinal manifestation, body weight). CDAI scores ranged approximately from 0 to 600, higher scores indicating greater disease activity.

    Time frame: At Week 12

  6. CD Cohort: Percentage of Participants With Corticosteroid-Free Remission

    Corticosteroid-free remission was defined as participants using oral corticosteroids at baseline (Week 0) who have discontinued oral corticosteroids and are in clinical remission at Week 52.

    Time frame: At Week 52

07

Results

Posted Jun 15, 2026

Participant flow

Participants took part in the study at 20 investigative sites in Japan from 04 June 2021.

Participant flow — Overall Study
MilestoneUC Cohort: Vedolizumab 300 mgCD Cohort: Vedolizumab 300 mg
Started4115
Completed00
Not completed4115
Withdrew: Ongoing in the study4115

Outcome measures

PrimaryUC Cohort: Percentage of Participants With Clinical Response at Week 12 Based on Modified Mayo Score

Clinical response was defined as a reduction of greater than or equal to (\>=) 2 points and \>=25 percent (%) in modified mayo score, and a decrease of \>=1 point in rectal bleeding sub-score or rectal bleeding sub-score of less than or equal to (\<=) 1 from baseline (Week 0). Mayo score was an instrument designed to measure disease activity of UC. Modified mayo score consisted of 3 sub-scores: stool frequency, rectal bleeding, and mayo endoscopic sub-score (findings on endoscopy), each graded from 0 to 3 with higher scores indicating more severe disease. These scores were summed to give a total score range of 0 to 9. Here, a higher score indicated more severe disease.

Time frame:
At Week 12
Reported as:
Number · percentage of participants
UC Cohort: Percentage of Participants With Clinical Response at Week 12 Based on Modified Mayo Score
percentage of participantsUC Cohort: Vedolizumab 300 mg
UC Cohort: Percentage of Participants With Clinical Response at Week 12 Based on Modified Mayo Score41.5 (26.3 to 57.9)
PrimaryCD Cohort: Percentage of Participants With Clinical Response at Week 12

Clinical response was defined as a reduction of \>=70 points in Crohn's Disease Activity Index (CDAI) score from baseline (Week 0). A CDAI was a multi-item instrument that measured severity of active Crohn's Disease monitored over 7 days included participant reported symptoms, physician-assessed signs, and laboratory markers. CDAI total score was equal to sum of weighted scores for subjective items (number of liquid/soft stools, degree of abdominal pain, general well-being); and objective items (use of anti-diarrhoeal medication, abdominal mass, haematocrit, presence of extraintestinal manifestation, body weight). CDAI scores ranged approximately from 0 to 600, higher scores indicated greater disease activity.

Time frame:
At Week 12
Reported as:
Number · percentage of participants
CD Cohort: Percentage of Participants With Clinical Response at Week 12
percentage of participantsCD Cohort: Vedolizumab 300 mg
CD Cohort: Percentage of Participants With Clinical Response at Week 1286.7 (59.5 to 98.3)
SecondaryUC Cohort: Percentage of Participants With Clinical Remission at Week 12 Based on Modified Mayo Score

Clinical remission was defined as a modified Mayo score of less than or equal to (\<=) 2, and no individual sub-score greater than (\>) 1. Mayo score was an instrument designed to measure disease activity of UC. Modified Mayo score consisted of 3 sub-scores: stool frequency, rectal bleeding, and Mayo endoscopic sub-score (findings on endoscopy), each graded from 0 to 3 with higher scores indicating more severe disease. These scores were summed to give a total score ranged of 0 to 9. Here, a higher score indicated a more severe disease.

Time frame:
At Week 12
Reported as:
Number · percentage of participants
UC Cohort: Percentage of Participants With Clinical Remission at Week 12 Based on Modified Mayo Score
percentage of participantsUC Cohort: Vedolizumab 300 mg
UC Cohort: Percentage of Participants With Clinical Remission at Week 12 Based on Modified Mayo Score0 (0.0 to 8.6)
SecondaryUC Cohort: Percentage of Participants With Mucosal Healing at Week 12

Mucosal healing was defined as a Mayo endoscopic sub-score of \<=1, in participants with baseline Mayo endoscopic sub-score of \>=2. Mayo score consisted of 4 sub-scores: stool frequency, rectal bleeding, mayo endoscopic sub-score (findings on endoscopy) and physician's global assessment, each graded from 0 to 3 with higher scores indicating more severe disease. These scores were summed to give a total score ranged of 0 to 12. Here, a higher score indicated a more severe disease.

Time frame:
At Week 12
Reported as:
Number · percentage of participants
UC Cohort: Percentage of Participants With Mucosal Healing at Week 12
percentage of participantsUC Cohort: Vedolizumab 300 mg
UC Cohort: Percentage of Participants With Mucosal Healing at Week 120 (0.0 to 8.6)
SecondaryUC Cohort: Percentage of Participants With Corticosteroid-Free Remission Based on Partial Mayo Score

Corticosteroid-free remission was defined as participants using oral corticosteroids at baseline (Week 0) who have discontinued oral corticosteroids and were in clinical remission based on partial Mayo score at Week 52. Clinical remission based on partial Mayo score was defined as a partial Mayo score of =\<2, and no individual sub-score \>1. Mayo score was an instrument designed to measure disease activity of UC. Partial Mayo score consists of 3 sub-scores: stool frequency, rectal bleeding, and physician's global assessment, each graded from 0 to 3 with higher scores indicated more severe disease. These scores are summed to give a total score range of 0 to 9. Here, higher scores indicated more severe disease.

Time frame:
At Week 52
Reported as:
Number · percentage of participants
UC Cohort: Percentage of Participants With Corticosteroid-Free Remission Based on Partial Mayo Score
percentage of participantsUC Cohort: Vedolizumab 300 mg
UC Cohort: Percentage of Participants With Corticosteroid-Free Remission Based on Partial Mayo Score0 (0.0 to 84.2)
SecondaryCD Cohort: Percentage of Participants With Clinical Remission at Week 12

Clinical remission was defined as a CDAI score of \<=150. A CDAI was a multi-item instrument that measured severity of active Crohn's Disease monitored over 7 days included participant reported symptoms, physician-assessed signs, and laboratory markers. CDAI total score was equal to sum of weighted scores for subjective items (number of liquid/soft stools, degree of abdominal pain, general well-being); and objective items (use of anti-diarrhoeal medication, abdominal mass, haematocrit, presence of extraintestinal manifestation, body weight). CDAI scores ranged approximately from 0 to 600, higher scores indicating greater disease activity.

Time frame:
At Week 12
Reported as:
Number · percentage of participants
CD Cohort: Percentage of Participants With Clinical Remission at Week 12
percentage of participantsCD Cohort: Vedolizumab 300 mg
CD Cohort: Percentage of Participants With Clinical Remission at Week 1246.7 (21.3 to 73.4)
SecondaryCD Cohort: Percentage of Participants With Enhanced Clinical Response at Week 12

Enhanced clinical response was defined as a reduction of \>=100 points in CDAI score from baseline (Week 0). A CDAI was a multi-item instrument that measured severity of active Crohn's Disease monitored over 7 days included participant reported symptoms, physician-assessed signs, and laboratory markers. CDAI total score was equal to sum of weighted scores for subjective items (number of liquid/soft stools, degree of abdominal pain, general well-being); and objective items (use of anti-diarrhoeal medication, abdominal mass, haematocrit, presence of extraintestinal manifestation, body weight). CDAI scores ranged approximately from 0 to 600, higher scores indicating greater disease activity.

Time frame:
At Week 12
Reported as:
Number · percentage of participants
CD Cohort: Percentage of Participants With Enhanced Clinical Response at Week 12
percentage of participantsCD Cohort: Vedolizumab 300 mg
CD Cohort: Percentage of Participants With Enhanced Clinical Response at Week 1280.0 (51.9 to 95.7)
SecondaryCD Cohort: Percentage of Participants With Corticosteroid-Free Remission

Corticosteroid-free remission was defined as participants using oral corticosteroids at baseline (Week 0) who have discontinued oral corticosteroids and are in clinical remission at Week 52.

Time frame:
At Week 52
Reported as:
Number · percentage of participants
CD Cohort: Percentage of Participants With Corticosteroid-Free Remission
percentage of participantsCD Cohort: Vedolizumab 300 mg
CD Cohort: Percentage of Participants With Corticosteroid-Free Remission0 (0.0 to 84.2)

Adverse events

Collected over From study start date to primary completion date (up to 3.99 years). Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
UC Cohort: Vedolizumab 300 mg0/41 (0%)3/41 (7.3%)19/41 (46.3%)
CD Cohort: Vedolizumab 300 mg0/15 (0%)6/15 (40%)14/15 (93.3%)
Most frequent serious events
Most frequent serious events
EventUC Cohort: Vedolizumab 300 mgCD Cohort: Vedolizumab 300 mg
COVID-19Infections and infestations0/411/15
Crohn's diseaseGastrointestinal disorders0/411/15
GastroenteritisInfections and infestations0/411/15
IleusGastrointestinal disorders0/411/15
Liver abscessInfections and infestations0/411/15
SepsisInfections and infestations0/411/15
Abdominal painGastrointestinal disorders1/410/15
Colitis ulcerativeGastrointestinal disorders1/410/15
UreterolithiasisRenal and urinary disorders1/410/15
Most frequent other events
Showing 10 of 21
Most frequent other events
EventUC Cohort: Vedolizumab 300 mgCD Cohort: Vedolizumab 300 mg
NasopharyngitisInfections and infestations8/415/15
Aphthous ulcerGastrointestinal disorders0/412/15
ArthritisMusculoskeletal and connective tissue disorders1/412/15
Crohn's diseaseGastrointestinal disorders0/412/15
Colitis ulcerativeGastrointestinal disorders3/410/15
AnaemiaBlood and lymphatic system disorders1/411/15
COVID-19Infections and infestations2/411/15
CoughRespiratory, thoracic and mediastinal disorders0/411/15
DepressionPsychiatric disorders0/411/15
DizzinessNervous system disorders1/411/15

Baseline characteristics

The full analysis set (FAS) included all participants who received at least 1 dose of study drug. UC cohort and CD cohort were analyzed separately. Numbers in the total column are simply data from the two cohorts combined and not part of the results produced within the study.

Age, Continuous
Age, Continuous(years)UC Cohort: Vedolizumab 300 mgCD Cohort: Vedolizumab 300 mgTotal
Mean49.5 ± 16.9341.5 ± 12.8447.4 ± 16.22
Sex: Female, Male
Sex: Female, Male(Participants)UC Cohort: Vedolizumab 300 mgCD Cohort: Vedolizumab 300 mgTotal
Female15722
Male26834
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)UC Cohort: Vedolizumab 300 mgCD Cohort: Vedolizumab 300 mgTotal
Hispanic or Latino000
Not Hispanic or Latino411556
Unknown or Not Reported000
Race (NIH/OMB)
Race (NIH/OMB)(Participants)UC Cohort: Vedolizumab 300 mgCD Cohort: Vedolizumab 300 mgTotal
American Indian or Alaska Native000
Asian411556
Native Hawaiian or Other Pacific Islander000
Black or African American000
White000
More than one race000
Unknown or Not Reported000
08

Study locations

20 sites
09

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: Yes — Takeda provides access to the de-identified individual participant data (IPD) for eligible studies to aid qualified researchers in addressing legitimate scientific objectives (Takeda's data sharing commitment is available on https://clinicaltrials.takeda.com/takedas-commitment?commitment=5). These IPDs will be provided in a secure research environment following approval of a data sharing request, and under the terms of a data sharing agreement.

Supporting information: Study protocol, Statistical analysis plan, Informed consent form, Clinical study report

Access criteria: IPD from eligible studies will be shared with qualified researchers according to the criteria and process described on https://vivli.org/ourmember/takeda/. For approved requests, the researchers will be provided access to anonymized data (to respect patient privacy in line with applicable laws and regulations) and with information necessary to address the research objectives under the terms of a data sharing agreement.

Data sharing details ↗ · vivli.org

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Jun 2021 to primary completion in May 2025, 47 months.

Results were first posted in Jun 2026, 1 year after primary completion.

Of 87 industry-sponsored phase 3 interventional studies under Colitis, Ulcerative, half reached primary completion within 47 months of starting (the median), counting those still running; a quarter within 31 and three quarters within 70. This study's 47 months is close to that.

Counting every sponsor, half of 101 studies reached it within 48 months; a quarter within 31 and three quarters within 75.

How these figures are worked out, and which studies are left out of them.

Registered
Feb 2, 2021
First posted
Feb 4, 2021
StartActual
Jun 4, 2021
Primary completionActual
May 30, 2025
CompletionEst.
Nov 30, 2027
Results first posted
Jun 15, 2026
Last update
Jun 15, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jun 15, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT04738942
Lead sponsor
Takeda
Responsible party
Sponsor
First posted
Feb 4, 2021
Start date
Jun 4, 2021
Primary completion
May 30, 2025
Completion
Nov 30, 2027 (estimated)
Results posted
Jun 15, 2026
Last update
Jun 15, 2026

Study contacts

Study Director
study director · Takeda

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is active, not recruiting, as verified in May 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Vedolizumab

Start the discussion